A Phase 2 interventional study of Bevacizumab and Carboplatin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 12 sites in India. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-27.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies testing bevacizumab in Breast Neoplasms — 9 open to participants now, 10 under way, none of them phase 3. Bevacizumab · Breast Neoplasms.
Among the 131 studies testing bevacizumab in Breast Neoplasms, this one is the 89th largest by enrollment of the 130 interventional ones that give a count, is one of 3 that started in 2011, is one of 89 in phase 2, and was the 100th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →9 of the 131 studies testing bevacizumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70 · Women only
Yukinori Ozaki · Sites in Japan
Ages 18+
Tongji Hospital · Sites in China
Ages 18+
Lebanese University · Sites in Lebanon
Ages 18+
Henan Cancer Hospital · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 96 · Phase 3 19 · Phase 4 4
First in 2000; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 58 across the 130 interventional studies. Of the 106 that completed or were terminated, 59 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 131 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
229 studies in Breast Neoplasms by Hoffmann-La Roche: 16 open now, 28 under way, 13 of them phase 3. Of 193 finished, 120 (62%) have results posted.
Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 143rd largest by enrollment of the 170 interventional ones that give a count, is one of 17 that started in 2011, is one of 65 in phase 2, and was the 74th registered.
Hoffmann-La Roche’s Breast Neoplasms studies by the year they started, since 1998.
3 of the studies testing bevacizumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05398861Henan Cancer HospitalUtidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer | 2026-12-30 |
| NCT07359404YING FANSacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | 2026-12-31 |
| NCT07150208Fudan UniversityT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 131 studies testing bevacizumab in Breast Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 229 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This multicenter study will assess the efficacy and safety of bevacizumab in combination with gemcitabine and cisplatin as first line treatment in participants with triple negative metastatic breast cancer. Participants will receive bevacizumab at a dose of 15 mg/kg intravenously (iv) every 3 weeks, plus gemcitabine (1000 mg/m2 iv) and carboplatin (iv to an area under curve [AUC]=2) on Days 1 and 8 of each 3-week cycle. Anticipated time on study treatment is until disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a combination therapy of bevacizumab with gemcitabine plus carboplatin.
Drug: Bevacizumab · Drug: Carboplatin · Drug: Gemcitabine
15 mg/kg iv every 3 weeks
Also known as: Avastin
to an AUC = 2, on days 1 and 8 of each 3-week cycle
1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
Progression-free Survival (PFS)
Progression free survival (PFS) was calculated in days from the date of registration until the earliest date of documented disease progression or death. The median PFS time with 95% confidence interval (CI) was estimated using Kaplan Meier method. The progression-free survival was assessed utilizing computer tomography (CT)/ magnetic resonance imaging (MRI)/bone scans and X-ray and Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
Time frame: From the date of registration until the disease progression or death (up to 1541 days).
Percentage of Participants Achieving an Overall Response
The overall response rate (ORR) was defined as complete response (CR) + partial response (PR). ORR was summarized using number and percentage along with two-sided 95% Pearson-Clopper CI. The overall response rate was assessed utilizing the RECIST v. 1.1. CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\<) 10 millimeter (mm). PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters.
Time frame: From the date of registration until the disease progression or death (up to 1541 days)
Percentage of Participants Achieving a Clinical Benefit Response (CBR)
Clinical benefit response was defined as a complete response (CR), partial response (PR) or stable disease (SD). CBR was assessed using Recist v.1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: From the date of registration until the disease progression or death (up to 1541 days)
Time to Progression (TTP)
Duration of time to progression (TTP) was estimated using the Kaplan-Meier method. The time to progression was calculated in days from the date of registration until the earliest date of documented disease progression.
Time frame: From the date of registration until the disease progression (up to 1541 days).
Overall Survival (OS)
Overall survival was measured from the date of the first study drug dose to the date of death from any cause. The median overall survival time with 95%CI was estimated using Kaplan-Meier method.
Time frame: From the date of registration until the disease progression or death (up to 1541 days)
Number of Participants With an Adverse Event (AE)
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Up to 28 days after termination of study treatment (approximately 1569 days)
Change From Baseline to Cycle 6 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)
The EORTC QLQ-C30 (version 3.0) questionnaire incorporates 9 multi scale items: 5 functional scales (physical, role, cognitive, emotional and social); 3 symptom scales (fatigue, pain and nausea \& vomiting); and a global health and quality-of-life scale. It contains 30 questions. The score for each item and the overall score ranges from 0 to 100. A high overall scale and subscale scores represent improved health status. However, in case of symptoms, higher scores suggest increased perception of these symptoms.
Time frame: Baseline, cycle 6
Change From Baseline in Systolic Blood Pressure (SBP)
Change from baseline in SBP was analyzed by overall response (CR+PR, SD+PD).
Time frame: Baseline, Cycle 6, 12 of treatment
Change From Baseline in Diastolic Blood Pressure (DBP)
Change from baseline in DBP was analyzed by overall response (CR+PR, SD+PD).
Time frame: Baseline, Cycle 6, 12 of treatment
| Milestone | All Participants |
|---|---|
| Started | 40 |
| Completed | 2 |
| Not completed | 38 |
| Withdrew: Death | 14 |
| Withdrew: Insufficient therapeutic response | 3 |
| Withdrew: Lost to follow-up | 10 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Disease progression | 4 |
Progression free survival (PFS) was calculated in days from the date of registration until the earliest date of documented disease progression or death. The median PFS time with 95% confidence interval (CI) was estimated using Kaplan Meier method. The progression-free survival was assessed utilizing computer tomography (CT)/ magnetic resonance imaging (MRI)/bone scans and X-ray and Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
| days | All Participants |
|---|---|
| Progression-free Survival (PFS) | 255 (157 to 465) |
The overall response rate (ORR) was defined as complete response (CR) + partial response (PR). ORR was summarized using number and percentage along with two-sided 95% Pearson-Clopper CI. The overall response rate was assessed utilizing the RECIST v. 1.1. CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers. Pathological lymph nodes must have short axis measures less than (\<) 10 millimeter (mm). PR: at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of diameters.
| percentage of participants | All Participants |
|---|---|
| Percentage of Participants Achieving an Overall Response | 50.0 (33.8 to 66.2) |
Clinical benefit response was defined as a complete response (CR), partial response (PR) or stable disease (SD). CBR was assessed using Recist v.1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| percentage of participants | All Participants |
|---|---|
| Percentage of Participants Achieving a Clinical Benefit Response (CBR) | 92.5 (79.6 to 98.4) |
Duration of time to progression (TTP) was estimated using the Kaplan-Meier method. The time to progression was calculated in days from the date of registration until the earliest date of documented disease progression.
| days | All Participants |
|---|---|
| Time to Progression (TTP) | 269.0 (182.0 to 551.0) |
Overall survival was measured from the date of the first study drug dose to the date of death from any cause. The median overall survival time with 95%CI was estimated using Kaplan-Meier method.
| days | All Participants |
|---|---|
| Overall Survival (OS) | 475.0 (358.0 to 759.0) |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
| participants | All Participants |
|---|---|
| Number of Participants With an Adverse Event (AE) | 24 |
The EORTC QLQ-C30 (version 3.0) questionnaire incorporates 9 multi scale items: 5 functional scales (physical, role, cognitive, emotional and social); 3 symptom scales (fatigue, pain and nausea \& vomiting); and a global health and quality-of-life scale. It contains 30 questions. The score for each item and the overall score ranges from 0 to 100. A high overall scale and subscale scores represent improved health status. However, in case of symptoms, higher scores suggest increased perception of these symptoms.
| units on a scale | All Participants |
|---|---|
| Baseline; physical (n=40) | 69.33 ± 20.963 |
| Change at Cycle 6; physical (n=28) | -8.82 ± 24.154 |
| Baseline; role (n=40) | 71.26 ± 25.311 |
| Change at Cycle 6; role (n=28) | -5.36 ± 22.705 |
| Baseline; cognitive (n=40) | 74.58 ± 24.745 |
| Change at Cycle 6; cognitive (n=28) | -4.17 ± 27.444 |
| Baseline; emotional (n=40) | 61.87 ± 22.396 |
| Change at Cycle 6; emotional (n=28) | -15.78 ± 23.929 |
| Baseline; social (n=40) | 65.42 ± 29.330 |
| Change at Cycle 6; social (n=28) | -8.33 ± 27.026 |
| Baseline; fatigue (n=40) | 42.21 ± 20.026 |
| Change at Cycle 6; fatigue (n=28) | 8.35 ± 25.785 |
| Baseline; pain (n=40) | 34.58 ± 25.428 |
| Change at Cycle 6; pain (n=28) | 13.09 ± 33.744 |
| Baseline; nausea and vomiting (n=40) | 16.67 ± 20.326 |
| Change at Cycle 6; nausea and vomiting (n=28) | 2.38 ± 19.082 |
| Baseline; global health & QOL (n=40) | 58.55 ± 17.750 |
| Change at Cycle 6; global health & QOL (n=28) | -3.86 ± 17.191 |
Change from baseline in SBP was analyzed by overall response (CR+PR, SD+PD).
| millimetre of mercury (mmHg) | All Participants |
|---|---|
| Baseline; CR+PR (n= 19) | 124.8 ± 12.86 |
| Change at cycle 6; CR+PR (n=14) | -4.6 ± 12.16 |
| Change at cycle 12; CR+PR at cycle 12 (n=5) | -4.0 ± 18.17 |
| Baseline; SD+PD (n= 18) | 123.6 ± 6.82 |
| Change at cycle 6; SD+PD at cycle 6 (n=13) | 0.2 ± 12.68 |
| Change at cycle 12; SD+PD at cycle 12 (n=4) | -6.3 ± 17.97 |
Change from baseline in DBP was analyzed by overall response (CR+PR, SD+PD).
| mmHg | All Participants |
|---|---|
| Baseline; CR+PR (n= 19) | 80.4 ± 9.65 |
| Change at cycle 6; CR+PR (n=14) | -4.1 ± 10.83 |
| Change at cycle 12; CR+PR (n=5) | -2.0 ± 14.83 |
| Baseline; SD+PD (n= 18) | 78.9 ± 7.58 |
| Change at cycle 6; SD+PD (n=13) | 2.3 ± 10.92 |
| Change at cycle 12; SD+PD (n=4) | 7.5 ± 12.58 |
Collected over Up to 28 days after termination of study treatment (approximately 1569 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Particiapants | — | 17/40 (42.5%) | 18/40 (45%) |
| Event | All Particiapants |
|---|---|
| Disease ProgressionGeneral disorders | 6/40 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/40 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 3/40 |
| PyrexiaGeneral disorders | 3/40 |
| AnaemiaBlood and lymphatic system disorders | 2/40 |
| NeutropeniaBlood and lymphatic system disorders | 2/40 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 2/40 |
| Pericardial EffusionCardiac disorders | 1/40 |
| Abdominal Pain LowerGastrointestinal disorders | 1/40 |
| FatigueGeneral disorders | 1/40 |
| Event | All Particiapants |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 10/40 |
| ThrombocytopeniaBlood and lymphatic system disorders | 9/40 |
| AnaemiaBlood and lymphatic system disorders | 5/40 |
| LeukopeniaBlood and lymphatic system disorders | 3/40 |
| Disease ProgressionGeneral disorders | 3/40 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 2/40 |
| StomatitisGastrointestinal disorders | 2/40 |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 47.5 ± 10.68 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 40 |
| Male | 0 |
The record gives a start of Feb 2011, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Carboplatin · Gemcitabine